Methods for increasing embryo implantation rate or fertility rate
Patent Information
- Application Number
- PCT/US2024/021056
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-03-23
- Filing Date
- 2024-03-22
- Publication Date
- 2025-01-16
AI Technical Summary
Current fertility treatments, such as hormone administration and surgical procedures, are invasive and costly, and fail to reliably enhance embryo implantation rates, leading to low conception success and adverse pregnancy outcomes like infertility and miscarriage.
Administration of glycosphingolipids or macrophages expressing glycosphingolipids to the reproductive structure, or use of conditioned media from co-cultured macrophages and glycosphingolipids, to promote embryo implantation by enhancing phagocytic activity, immune tolerance, and trophoblast invasion.
Increases embryo implantation and fertility rates by modulating macrophage differentiation and function, improving tissue remodeling and immune suppression, thereby facilitating successful implantation and placentation.
Smart Images

Figure US2024021056_16012025_PF_FP_ABST
Abstract
Description
Docket no. 203-054PCT METHODS FOR INCREASING EMBRYO IMPLANTATION RATE OR FERTILITY RATE CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Application No. 63 / 454,174, filed on 23 March, 2023, the entire disclosure of which is incorporated herein by reference. BACKGROUND OF THE INVENTION
[0002] Implantation is defined as the process by which the embryo attaches to the endometrial surface of the uterus and invades the epithelium and then the maternal circulation to form the placenta. It is a highly organized process that involves an interaction between a receptive uterus and a competent embryo.
[0003] In humans, the chance of conception per cycle is relatively low (~30%) and two-third of lost pregnancies occur because of implantation failure. Defective implantation leads to adverse pregnancy outcomes including infertility, spontaneous miscarriage, intrauterine fetal growth restriction and preeclampsia.
[0004] Current treatments to enhance fertility include administration of fertility drugs, including hormones or other substances that act by accelerating ovulation, and / or surgical procedures, some of which can be very invasive and expensive.
[0005] Accordingly, there remains a present but unsatisfied need to find a reliable method to increase embryo implantation rate. The present invention addresses this need and other needs. BRIEF SUMMARY OF THE INVENTION
[0006] Provided herein are methods for increasing embryo implantation or fertility in a subject. According to some embodiments, a composition comprising one or more glycosphingolipids is administered to the reproductive structure of the subject. According to another embodiments, one or more macrophages that express glycosphingolipid are administered to a reproductive structure of the subject. According to yet another embodiment, the composition comprises a condition medium, which is obtained from co- culturing one or more macrophages with one or more glycosphingolipids.Docket no. 203-054PCT
[0007] Also provided are methods for increasing embryo implantation or fertility in a subject, by administering at least one embryo to the reproductive structure of the subject, wherein the embryo expresses a glycosphingolipid.
[0008] The details of one or more embodiments of the invention are set forth in the description below. Other features or advantages of the present invention will be apparent from the following detailed description of several embodiments, and also from the appending claims. Statements containing these terms should be understood not to limit the subject matter described herein or to limit the meaning or scope of the patent claims below. This summary is a high-level overview of various aspects of the invention and introduces some of the concepts that are further described in the Detailed Description section below. This summary is not intended to identify key or essential features of the claimed subject matter, nor is it intended to be used in isolation to determine the scope of the claimed subject matter. The subject matter should be understood by reference to appropriate portions of the entire specification, any or all drawings and each claim. BRIEF DESCRIPTION OF THE DRAWINGS
[0009] Fig.1: characterization of the isolated extracellular vesicles derived from ESCs, and the GSL profiling of ESCs and ESC-secreted EVs by MS analysis.
[0010] Fig. 1A is an electron microscopic images of EVs derived from human embryonic stem cells (ESCs) after heavy-metal staining (Scale bars: 100 nm).
[0011] Fig. 1B is an image of western blot analysis for CD9 and CD63. Lysates were prepared from ESCs (Cells) and ESC-secreted EVs, and subjected to western blot analyses with immunostaining for CD9, CD63, and β-actin.
[0012] Fig. 1C shows the diameter distribution of EVs, assessed by nanoparticle tracking analysis using a NanoSight NS3000 system.
[0013] Fig. 1D is an assembly of mass spectrum analysis of the glycosphingolipids (GSLs) from ESCs and ESC-secreted EVs, in the neutral and acidic portions of lipid extract.
[0014] Fig. 2: Transfer of GSLs from EVs to immune cells.
[0015] Top portion Fig. 2A includes an assembly of flow cytometry images to show the expression of GHCer, SSEA3Cer, and SSEA4Cer in CD14 subset of human peripheral blood mononuclear cells (PBMCs), incubated with or without 100 μg ESC-secreted EVs. Gray, isotype control; dashed line, cells treated with PBS as a control; bold black lines, cells treatedDocket no. 203-054PCT with ESC-secreted EVs.
[0016] Bottom portion of Fig. 2A includes an assembly of immune-fluorescence analysis images of GHCer, SSEA3Cer, and SSEA4Cer of isolated monocytes incubated with / without 100 μg ESC-secreted EVs. The nuclei were stained with DAPI (blue color). Scale bar, 30 μm.
[0017] Top portion Fig. 2B includes an assembly of flow cytometric analysis of the expression of GHCer, SSEA3Cer, and SSEA4Cer in T cells in PBMCs gated by CD4+after incubation with / without ESC-secreted EVs.
[0018] Bottom portion of Fig. 2B includes an assembly of flow cytometry images, illustrating the expressions of GHCer, SSEA3Cer, and SSEA4Cer in isolated T cells activated with / without CD3 / CD28 Dynabeads, incubated with / without 100 μg ESC-secreted EVs. Gray, isotype control; dashed line, cells treated with PBS as a control; bold black lines, cells treated with ESC-secreted EVs.
[0019] Top portion of Fig. 2C is the protocol for human monocyte differentiation into macrophages.
[0020] Bottom portion of Fig. 2C is an assembly of flow cytometry images, illustrating the expression of GHCer, SSEA3Cer, and SSEA4Cer in ESC EV- / β3GALT5-knockout (KO) EV treated-macrophages, obtained from the protocol above. Gray, isotype control; dashed line, cells treated with PBS as a control; bold black lines, cells treated with EVs.
[0021] Top portion of Fig. 2D is the protocol for human monocytes differentiation into macrophages,
[0022] Bottom portion of Fig. 2D is an assembly of flow cytometry images, illustrating the expression of GHCer and SSEA3Cer in GSL-treated macrophages, obtained from the protocol at the top portion of Fig. 2D. Gray, isotype control; dashed line, cells treated with PBS as a control; bold black lines, cells treated with synthetic GSLs.
[0023] Fig. 3: The effects on mRNA expression of pro-inflammatory factors and decidual macrophage-related genes by globo-series GSLs.
[0024] Fig. 3A is an assembly of bar graphs showing mRNA expressions of iNOS (M1 marker), CD206 (M2 marker), and CD209 (decidual macrophage marker) in ESC EV-treated macrophages.
[0025] Fig. 3B is an assembly of bar graphs showing mRNA expressions of CD marker-Docket no. 203-054PCT related genes: iNOS, CD206, and CD209, the pro-inflammatory factor-related genes: TNF, MIP1α, IL23, and IL6, the decidual macrophage-related genes: TREM2, NRP1, CXCL1, and MMP9, in PBS-treated, GlcCer-treated, GHCer-treated, or SSEA3Cer-treated macrophages.
[0026] The data are shown as the means ± SD standard deviations for PCR reactions performed in triplicate (N=3). * P< 0.05 versus control macrophages; **P< 0.01 versus control macrophages after paired t-tests and one-way ANOVA with Tukey post-hoc test.
[0027] Fig.4: Enhancement of the phagocytic activity of macrophages by globo-series GSLs from ESC-secreted EVs.
[0028] Top of portion of Fig. 4A is the protocol of human monocytes differentiation into macrophages, treated with 100 μg EVs or 30 µM synthetic GSLs at day 7 for 2 days.
[0029] Bottom portion of Fig.4A includes graphs illustrating the phagocytic activities of the EV-treated- / GSL-treated macrophages obtained according to the protocol above. The GSLs included GlcCer, GHCer, and SSEA3Cer and the phagocytic activities of the macrophages were analyzed by flow cytometry. Latex beads conjugated with FITC were mixed with the PBS-treated macrophages at 4°C as a negative control.
[0030] Fig. 4B is a bar graph illustrating the increased phagocytic activity of GSL-treated macrophages is mediated through TREM2, as phagocytic activity of GSL-treated monocytes incubated with neutralizing antibody targeting TREM2 (10 μg / ml) is reduced. The data are shown as means ± SD (N=5). * P< 0.05 versus control monocytes after one-way ANOVA with Tukey post-hoc test.
[0031] Fig. 5: Effects of the culture of macrophages with globo-series GSLs on T cell proliferation.
[0032] Top portion of Fig.5A is the protocol of monocytes differentiation into macrophages with synthetic GSLs (GHCer or SSEA3Cer), and coculture with autologous T cells.
[0033] Bottom portion of Fig. 5A is an assembly of flow cytometry images showing the expression of GSLs on the surface of T cells, after incubation with the GSL-treated macrophages, anti-CD3 and anti-CD28. Gray, isotype control antibodies; bold black lines, anti- GHCer or anti-SSEA3Cer antibodies.
[0034] The flow cytometry images of top portion of Fig. 5B show CFSE proliferation profiles of GlcCer-, GHCer-, and SSEA3Cer-treated macrophages.
[0035] The bar graph of bottom portion Fig. 5B shows T cell proliferation induced byDocket no. 203-054PCT GlcCer-, GHCer-, SSEA3Cer-treated and PBS-treated macrophages profiles (control). The T cell proliferation was evaluated by counts of proliferating cells. The data are shown as the means ± SD standard deviations (N=5); * P< 0.05 versus control macrophages after one- way ANOVA with Tukey post-hoc test.
[0036] Fig. 6: The globo-series GSLs promote trophoblast invasion
[0037] The effects of GSL-treated macrophages on the invasion of the human trophoblast cell line HTR-8 / SVneo was evaluated.
[0038] Top portion of Fig. 6 shows monocytes were stimulated to differentiate into macrophages with synthetic GSLs and the conditional medium was collected (as control). HTR-8 / SVneo cells (1x105) were seeded with the conditional media (control) and GSL- treated macrophages.
[0039] Lower left portion of Fig.6 are microscopic images showing HTR-8 / SVneo invasion, induced by control medium and GlcCer-, GHCer-, SSEA3Cer-treated macrophages. The cell numbers were quantified by counting with Image J software (total counts / field).
[0040] Right lower portion of Fig. 6 is a bar graph, showing GlcCer- and GHCer- treated macrophages significantly increased HTR-8 / SVneo invasion compared to control. The data are shown as the means ± SD standard deviations (N=5); **P< 0.01 versus control macrophages; ***P< 0.001 versus control macrophages after one-way ANOVA with Tukey post-hoc test.
[0041] Fig. 7: The globo-series GSL expression in clinical decidual tissues from elective first-trimester abortions
[0042] Fig. 7A includes two microscopic images showing the expression of SSEA3Cer in tissue sections of human decidua obtained from subjects with normal pregnancies undergoing elective first-trimester termination of pregnancy. Expression of SSEA3Cer in formalin-fixed, paraffin-embedded decidual tissue sections was determined by IHC staining with anti-SSEA3Cer antibody. A representative positive staining image and isotype control are shown (original magnification 20X).
[0043] Fig. 7B includes multiplex immunohistochemistry images, showing the decidual microenvironment of elective first-trimester abortions. The images show the presence of CD209+macrophages with variable expression of SSEA3Cer in the decidual microenvironment from elective first-trimester abortions (arrows). Scale bars, 20 μm.Docket no. 203-054PCT
[0044] Fig. 8 shows the role of EV-associated GSLs in driving the changes in macrophages for immune suppression, tissue remodeling, and trophoblast invasion in decidual microenvironment.
[0045] Fig.9: The transfer of GSLs from pluripotent stem cells (PSCs)-derived EVs enhance the phagocytic activity of macrophages.
[0046] Fig. 9A shows the human monocytes were differentiated into macrophages, and treated with / without 70 μg PSC-derived EVs at day 7 for 2 days during monocyte polarization. Flow cytometry was performed using specific antibodies to measure the expressions of GHCer, SSEA3Cer, and SSEA4Cer in EV treated macrophages. Gray, isotype control; dashed line, cells treated with PBS as a control; bold black lines, cells treated with EVs.
[0047] Fig. 9B includes graphs illustrating the phagocytic activities of the PSC EV-treated macrophages obtained according to the protocol above. The EVs included HUES6, HUES6 KO, and iPS71 and the phagocytic activities of the macrophages were analyzed by flow cytometry. Latex beads conjugated with FITC were mixed with the PBS-treated macrophages at 4°C as a negative control. The EV-treated macrophages were harvested from the culture medium for phagocytic assays.
[0048] Fig.10: Dot-blot analysis for determination of GSL concentration.
[0049] Fig.10 Panel A is an image of serial dilutions of the synthetic GHCer in the following samples: synthetic GHCer as the standard, the conditioned medium collected from the PBS- (Ctrl), GHCer-, and SSEA3Cer-treated macrophages , and the medium alone, probed with GHCer mAb.
[0050] Fig.10 Panel B is a line graph, showing the signals from GHCer standards were quantified with the ImageQuant software.
[0051] Fig.10 Panel C shows the signal volume is the integration of signal intensity over the area of the dot. The linear regression curve yields an equation as presented. Based on this equation, each sample signal in the linear range was converted to an absolute quantity of GHCer.
[0052] Fig.10 Panel D shows the serial dilutions of the synthetic SSEA3Cer in following samples: synthetic GHCer as the standard, the conditioned medium collected from the PBS- (Ctrl), GHCer-, and SSEA3Cer-treated macrophages, and the medium alone, probed withDocket no. 203-054PCT SSEA3Cer mAb.
[0053] Fig.10 Panel E is a line graph, showing the signals from SSEA3Cer standards were quantified with the ImageQuant software.
[0054] Fig.10 Panel F shows the signal volume is the integration of signal intensity over the area of the dot. The linear regression curve yields an equation as presented. Based on this equation, each sample signal in the linear range was converted to an absolute quantity of SSEA3Cer.
[0055] Fig. 11: The globo-series GSLs promote trophoblast invasion
[0056] Top portion of Fig. 11 is an assembly of flow cytometry images, illustrating the expression of GHCer and SSEA3Cer in GSL-treated HTR-8 / SVneo cells. Gray, isotype control; dashed line, cells treated with PBS as a control; bold black lines, cells treated with synthetic GSLs.
[0057] Lower portion of Fig. 11 includes an image and a bar graph showing HTR-8 / SVneo invasion, induced by PBS-, GlcCer-, GHCer-, and SSEA3Cer-treated. The cell numbers were quantified by colorimetric quantification. The data are shown as the means ± SD standard deviations (N=3); *P< 0.05 versus control HTR-8 / SVneo cells; **P< 0.01 versus control HTR-8 / SVneo cells after one-way ANOVA with Tukey post-hoc test.
[0058] Fig.12: The transfer of GSLs from trophoblast-derived EVs enhances the phagocytic activity of macrophages
[0059] Fig. 12 Panel A includes the isolation of EVs derived from primary trophoblasts by ultracentrifuge. Immunogold staining of the isolated EVs using anti-CD63 antibodies, followed by gold-particle-conjugated secondary antibody. Scale bars, 100 nm. The diameter distribution of EVs was examined with nanoparticle tracking analysis using a ZetaView system. Human monocytes were treated with / without 100 mg trophoblast-derived EVs from five donors (EV1–EV5) during macrophage polarization. Flow cytometry was performed using specific antibodies to measure the expressions of GHCer, SSEA3Cer, and SSEA4Cer in EV-treated macrophages. Gray, isotype control; dashed line, cells treated with PBS as a control; bold black lines, cells treated with EVs.
[0060] In Fig. 12 Panel B, the EV-treated macrophages were harvested from the culture medium for phagocytic assays. Latex beads conjugated with FITC were mixed with PBS treated or trophoblast EV-treated macrophages for 24 h. Latex beads conjugated withDocket no. 203-054PCT FITC were mixed with the PBS-treated macrophages at 4℃ as a negative control (gray). The data are shown as means ± SD (n = 5). *p < 0.05 versus control monocytes after t test. DETAILED DESCRIPTION OF THE INVENTION
[0061] Unless defined otherwise, all technical and scientific terms used herein have the same meanings as is commonly understood by one of skill in the art to which this invention belongs.
[0062] As used herein, the articles “a” and “an” refer to one or more than one (i.e., at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element.
[0063] The term “comprise” or “comprising” is generally used in the sense of include / including which means permitting the presence of one or more features, ingredients or components. The term “comprise” or “comprising” encompasses the term “consists” or “consisting of.”
[0064] All numbers are modified by the term “about”. As used herein, the term “about” refers to a range of ±10% of a specified value.
[0065] The term “subject” can refer to a female animal belonging to any species desires to produce an offspring or in need of treatment for infertility. Subjects include warm-blooded animals, such as mammals, such as a primate, and, more preferably, a human. Non-human primates are subjects as well. The term subject includes domesticated animals, such as cats, dogs, etc., livestock (for example, cattle, horses, pigs, sheep, goats, etc.) and laboratory animals (for example, mouse, rabbit, rat, gerbil, guinea pig, etc.). Thus, veterinary uses and medical formulations are contemplated herein.
[0066] The use described herein is applicable to any female subject to increase fertility or embryo implantation, regardless of whether fertility is normal, diminished (sub- fertile) or not (fertile). In one embodiment, the composition of the present invention can be used to treat sub-fertility, i.e., to improve the likelihood of successful fertilization. Methods for Increasing Embryo Implantation Rate or Fertilization Rate
[0067] EVs are produced by the embryo and they carry specific cargoes, including GSLs. The EV-associated GSLs seem to drive the differentiation of monocytes into macrophages with properties that promote embryo implantation, including (i) tissue remodeling: enhance of phagocytic activity for the removal of apoptotic cells and enhanced immunity againstDocket no. 203-054PCT pathogens, (ii) down-regulation of T cell proliferation in support of maternal tolerance of the embryo, and (iii) the promotion of trophoblast invasion in decidual microenvironment.
[0068] The GSLs, such as GHCer and SSEA3Cer, from ESC-secreted EVs could be incorporated into monocytes and primed the differentiation toward decidual-like macrophages displaying features favoring embryo implantation and decidual placentation.
[0069] The co-culture of M0macrophages with EVs or specific synthetic globo-series GSLs lead to polarization and down-regulation of the M1marker, iNOS, while the decidual macrophage marker, CD209, was up-regulated. The EVs or specific GSLs enhanced the phagocytic activity, the expression of the protease (MMP9), and the pro-angiogenesis factor (NRP1); and also promoted the trophoblast invasions, which lead to prime tissue remodeling and conceivably facilitate embryo implantation and placentation. The suppression of T cell proliferation and the expression of inflammatory substances (TNF, MIP1α, IL23, and IL6) enhances immune suppression in the decidual milieu. In addition, co-culture of M0macrophages with GSLs increased the capacity for trophoblast invasion.
[0070] Without being bound by any particular theory, it is believed globo-series GSLs from ESC-secreted EVs or synthetic globo-series GSLs, promote changes in macrophages that indicate roles of EV-associated GSLs in tissue remodeling, immune-tolerance, and trophoblast invasion for successful implantation (Fig. 8).
[0071] According to some embodiments, methods for increasing embryo implantation rate or fertility in a subject are provided, comprises the step of administering a composition comprising therapeutically effective amount of glycosphingolipid, to a reproductive structure of the subject.
[0072] The reproductive structure can be a vagina, cervix, uterus, fallopian tube, and combinations thereof in a female mammal.
[0073] In one embodiment, the glycosphingolipid is from PSC-secreted EVs. In another embodiment, the glycosphingolipid is synthetic glycosphingolipid.
[0074] None limiting examples of the glycosphingolipid include Globo H ceramide (GHCer), stage-specific embryonic antigen-3 ceramide (SSEA3Cer), stage-specific embryonic antigen-4 ceramide (SSEA4Cer), or a derivative thereof.
[0075] In one embodiment, the glycosphingolipid is expressed on the surface of a macrophage or an embryo, expressed as “+”.Docket no. 203-054PCT
[0076] The expression level of glycosphingolipid on the surface of a macrophage or an embryo is “+” as long as the expression is positive relative to a negative control macrophage population or an embryo, expressed as “-“.
[0077] In one embodiment, the expression level of glycosphingolipid on the surface of a macrophage or embryo is quantified by exposing the macrophage or embryo to a monoclonal antibody against GHCer, SSEA3Cer or SSEA4Cer, followed by sorting of the macrophage or embryo using flow cytometry (e.g. Gallios, commercially available from Beckman Coulter, Inc., USA).
[0078] In another embodiment, the composition comprises a conditioned medium. The conditioned medium, known as the liquid phase of a cell culture environment, is obtained by co-culture the macrophages with glycosphingolipid during a specific period of culture, such as at least 24 hours, at least 48 hours, at least 60 hours, at least 72 hours to 7 days, 8 days, 9 days, 10 days.
[0079] In one embodiment, the composition is simultaneously administered with or after the administration of semen, an oocyte, or an embryo into the reproductive structure of the subject.
[0080] In another embodiment, the method further comprises the administration of one or more therapeutic agent that enhance embryo implantation, including, but not limited to, GnRH agonist, immunosuppressant such as tacrolimus, sirolimus, cyclosporin and anti- TNF-α therapy.
[0081]
[0082] The present invention is further illustrated by the following examples, which are provided for the purpose of demonstration rather than limitation. Those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.
[0083] Material and Method
[0084] Collection of ESC-derived EVs and trophoblast-derived EVs
[0085] EVs were collected by ultracentrifugation. Briefly, confluent ESCs were washed with phosphate-buffered saline (PBS), and the medium was replaced with DMEM / F12 containing 1% knock-out serum replacer (Invitrogen) for 24 h. The culture supernatant wasDocket no. 203-054PCT removed and passed through a 0.22 μm filter (Millipore, Billerica, MA, USA). The placental tissues were carefully removed decidua to access placental villous tissue, and cut into explants / fragments of 5 mm. Explants were cultured in 100 mm culture dishes in DMEM- F12 supplemented with 1% antimycotic / antibiotics, 10% EV-free FBS for 72 hrs for generation of trophoblast-derived EVs. The culture supernatant was removed and passed through a 0.22 μm filter (Millipore).
[0086] Afterward, the conditioned medium was centrifuged at 1,200 g for 10 min and then at 10,000 g for 30 min twice. The supernatant was collected after centrifugation at 100,000 g for 1 h. The resulting pelleted EVs were resuspended in PBS, and the protein concentration was determined with the Pierce Micro-BCA kit (Thermo Fisher Scientific, USA). EVs were aliquoted and stored at -20ºC until use.
[0087] Electron microscopy and immunogold labelling
[0088] Isolated EVs were diluted in PBS and loaded onto Formvar carbon-coated grids (Ted Pella Inc., USA). After washing with PBS and fixing with 8% glutaraldehyde in PBS for 30 min, heavy-metal staining was performed on the grids using 3% uranyl acetate. Excess fluid was removed and the grids were allowed to dry before examination with a transmission electron microscopy (HITACHI HT-7800, Germany).
[0089] Immunolabelling was performed by mounting the concentrated samples on carbon- coated, glow discharged 300 mesh Ni grids (Electron Microscopy Sciences, USA). Grids were blocked with 0.5% bovine serum albumin (BSA) (Sigma-Aldrich, USA) in PBS and incubated with anti-CD63 antibody (Abcam Inc., MA, USA) 1:50 in 0.5% BSA in PBS for overnight at 4 °C. After incubation, grids were washed 3 times with PBS and incubated with secondary antibody goat anti-mouse conjugated with 4 nm colloidal gold (Jackson ImmunoResearch, USA) 1:20 in 0.5% BSA in PBS. Samples and secondary antibody were incubated for 1 h at room temperature. The grids were then washed with 3 drops of PBS. The grids were finally washed with PBS before staining with 2 drops of uranyl acetate and blotted dry. Images were obtained with a transmission electron microscope (HITACHI HT- 7800).
[0090] Nanoparticle tracking analysis
[0091] Determination of size distribution and quantification of EVs were conducted by nanoparticle tracking analysis using a NanoSight NS3000 System (Malvern Instruments Ltd.,Docket no. 203-054PCT UK) and ZetaView (Particle Metrix, Germany). Samples suspended and diluted in 0.22 μm pre-filtered PBS to a final volume of 1 ml. The diameters of EVs were measured in three independent experiments and are presented as means ± standard deviation (SD).
[0092] Western blotting
[0093] Lysates were prepared from ESCs with RIPA buffer containing NP-40, protease inhibitors (Roche, USA), and tyrosine and serine / threonine phosphatase inhibitors (Sigma- Aldrich). Fifty μg protein extracts of cells and EVs were separated on 4–12% NuPAGE (Invitrogen, USA) and transferred to polyvinylidene difluoride membranes (Millipore, USA). The membranes were incubated with primary antibodies at 4°C overnight followed by alkaline phosphatase-conjugated secondary antibodies (Jackson Immunoresearch Laboratories, USA) at room temperature for 1 h. Then, the membrane was scanned with a Typhoon 9400 Variable Mode Imager (GE Healthcare Bio-Sciences, USA) to detect the fluorescent signals. The anti-CD63 antibody was purchased from Abcam Inc. Antibody against CD9 was purchased from System Biosciences (USA). β-actin (Sigma-Aldrich) was used as an internal control.
[0094] Extraction and permethylation of GSLs
[0095] The two-phase Folch method has been the commonly used protocol for GSL extraction. The improved Folch method to extract the GSLs from approximately 5x106ESCs and ESC-secreted EVs was used, as described below. The ESC-secreted EVs (about 150-200 μg) were collected and resuspended in 1 ml of CHCl3: MeOH: ddH2O (4:8:3) extraction buffer to extract GSLs; the procedure was performed four times. Then, the extracted pool was blow-dried under N2, followed by saponification overnight. Next, the total GSLs (including neutral and acidic GSLs) were captured and enriched using a mixed- mode polymeric sorbent cartridge (Oasis MAX cartridge, USA). To separate the neutral and acidic GSLs, different solvents were used for elution. First, 100% methanol was used to elute the neutral GSLs from the MAX cartridge. Next, the acidic GSLs were eluted with 0.2 M NH4OAc in methanol. Due to the presence of NH4OAc in acidic GSL elutions, the acidic fraction was next desalted using anion-exchange chromatography (Oasis HLB cartridge). Both neutral and acidic GSLs were subjected to speed-vac drying, followed by permethylation using a NaOH / DMSO method with iodomethane (Merck, Darmstadt, Germany), as previously described (Smith and Prieto, 2001). Permethylated neutral andDocket no. 203-054PCT acidic GSLs were mixed with 2,5-dihydroxybenzoic acid (DHB) matrix (Sigma-Aldrich) and the spectrum profile was acquired by MALDI / TOF MS (SCIEX 5800 TOF / TOF) with positive-ion mode for 4000 laser shots accumulation on random sampling mode.
[0096] Production of synthetic GSLs
[0097] GHCer and SSEA3Cer with fatty acid tail 16:0 were prepared by modification of previously reported methods (Yu et al., 2018). In brief, lactosyl sphingosine was assembled with sugars by chemo-enzymatic synthesis (Tsai et al., 2013a) to generate globo H- sphingosine, which were then coupled with a fatty acid, respectively, to yield GHCer. To prepare SSEA3Cer, GHCer was digested with α1, 2-fucosidase according to the manufacturer’s instructions. Briefly, GHCer was mixed with fucosidase in 1X GlycoBuffer1 (New England Biolabs, USA) and incubated at 37°C for 2 h. After incubation, the enzyme was inactivated at 100°C for 10 min. Then, the digested GHCer was subjected to MS spectral analysis without further purification. GHCer and SSEA3Cer were each dissolved in PBS to a concentration of 2 mg / ml. GlcCer was purchased from Sigma-Aldrich and dissolved with 4 mg / ml BSA solution to a concentration of 2 mg / ml. The GSLs were aliquoted and stored at 4°C until use.
[0098] Isolation of immune cells and monocyte differentiation
[0099] PBMCs from healthy donors were isolated using Ficoll-Paque (GE Healthcare Bio- Sciences, USA). These procedures were conducted in accordance with relevant guidelines and regulations and approved by the Institutional Review Board of Chang Gung Medical Foundation. Monocytes and T-cells were prepared from PBMCs by a two-step procedure. First, monocytes were isolated from PBMCs as the positive fraction using CD14 MicroBeads (Miltenyi Biotec, Germany). Then, the negative fraction was incubated with a CD4 T-Cell MicroBead Cocktail (Miltenyi Biotec) to isolate the T-cells. After purification, those monocytes or T-cells were cultured in RPMI 1640 (Corning, USA) supplemented with 100 IU / ml penicillin (Lonza, Switzerland), 100 mg / ml streptomycin (Lonza), 10% heat-inactivated fetal bovine serum (FBS, HyClone) A portion of the isolated monocytes was differentiated into macrophages by treatment with 25 ng / ml recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) (PeproTech, Germany) for 7 days, and then 100 ng / ml lipopolysaccharides (LPS) (Sigma-Aldrich) and 25 ng / ml interferon-γ (IFN-γ) (PeproTech) for another 2 days. On day 7 of culture, duringDocket no. 203-054PCT monocyte differentiation, 100 μg of ESC-secreted EVs or 30 μM synthetic GSLs was added the cells (the EV- or GSL-treated macrophages). Since macrophages are difficult to dislodge from culture dish, a special detachment solution (Macrophage Detachment Solution DXF, Promo Cell) was used to detach the EV or GSL treated macrophages for the experiments after incubation for 40 min at 2 to 8°C. The detachment progress was monitored using microscope; when necessary, another 20 min incubation was used to enforce the cell release.
[0100] Flow cytometric analysis
[0101] Antibodies against human CD4-PE and CD14-Brilliant Violet 421 were purchased from Biolegend (USA). Monoclonal antibody against GHCer was prepared from the VK9 (anti-mouse IgG antibody) hybridoma provided by Dr. G. Ragupathi (Dr. G. Ragupathi). Monoclonal antibodies against SSEA3Cer (MC-631, anti-rat IgM antibody) and SSEA4Cer (MC-813-70, anti-mouse IgG antibody) were purchased from R&D Systems (USA). For cell-surface CD marker and GSL staining, the resuspended cells were incubated with optimal concentrations of the primary antibodies and fluorescent-labeled secondary antibodies for 30 min at 4 C and analyzed with an SA3800 spectral cell analyzer (Sony, Japan). Data from flow cytometric studies were analyzed using FlowJo software (BD, USA).
[0102] Cytospin and immunofluorescence analysis
[0103] The EV-treated monocytes were spun with a cytocentrifuge (Thermo Fisher Scientific) and fixed in 4% paraformaldehyde in PBS. Then, immunofluorescence analysis was performed. Briefly, cytospin samples were treated with 5% (v / v) normal goat serum (Vector Laboratories, USA) for 30 min to block nonspecific binding and then incubated with monoclonal anti-GSL antibody (VK9 for GHCer, MC-631 for SSEA3Cer, and MC-813-70 for SSEA4Cer) at 4°C overnight. Afterward, samples were washed three times with PBS-Tween 20 and an Alexa Fluor 488-conjugated donkey anti-mouse IgG antibody (Invitrogen) or an Alexa Fluor 488-conjugated goat anti-rat IgM antibody (Invitrogen) was added, followed by 60 min of incubation. Nuclei were counterstained with 4’6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich). Immunoreactive cells were examined with a fluorescence microscope (Nikon, Japan).
[0104] Quantitative real-time PCR
[0105] Total RNA was extracted from GSL-treated macrophages with TRIzol reagent (Invitrogen), and 1 μg of RNA was reversely transcribed into cDNADocket no. 203-054PCT using Omiscript RT (Qiagen, Germany). cDNA (20 ng) mixed with 1X SYBR Green Master Mix (Applied Biosystems, USA) was used to perform real-time quantitative PCR on an Applied Biosystems 7500 instrument. The values of the cycle threshold were used to calculate the fold differences in gene expression relative to the expression of the housekeeping gene, GAPDH.
[0106] Phagocytic assay
[0107] The phagocytic activity of macrophages was analyzed by flow cytometry using Fluorescein Isothiocyanate-Dextran (FITC-dextran, 40kDa, Sigma-Aldrich). Briefly, FITC-dextran was mixed with the EV- or GSL-treated macrophages at 37°C for 24 h. Then the cells were washed twice with PBS. To show that the phagocytic ability of macrophages was mediated through TREM2, GSL-treated macrophages were first incubated with a neutralizing antibody against TREM2 (R&D Systems, cat: MAB17291, 10 μg / ml) to block TREM2 signaling and then incubated with FITC-dextran for 2 h. As a negative control, FITC-dextran was mixed with the PBS-treated macrophages at 4°C. These macrophages did not engulf FITC–dextran when incubated at 4°C. The flow cytometric data were analyzed using FlowJo software.
[0108] T-cell proliferation assay
[0109] GSL-treated macrophages (1x105cells) attached to the bottom of culture plates were cocultured with 5x105autologous T-cells labeled with the cell permeant dye, carboxyfluorescein diacetate succinimidyl ester (CFSE) (eBioscience) and treated with 1 μl anti-CD3 antibody (OKT3, BioLegend) and 5 μl anti-CD28 antibody (CD28.2, BioLegend) in 24-wells plate for 72 h. The CFSE intensity in cells was measured by flow cytometry. The flow cytometric data were analyzed using FlowJo software. As controls, the unstimulated, CFSE-labeled T-cells displayed the CFSE intensity of non-divided cells, while the cells without labeling showed the auto-fluorescence of the cells and the limits of detectable cell divisions. For the quantification of T-cell proliferation, the number of proliferating T-cells was normalized with the PBS-treated macrophages as controls.
[0110] Trophoblast invasion assay
[0111] The monocytes were stimulated to differentiate into macrophages withDocket no. 203-054PCT synthetic GSLs at day 7 for 2 days. After washing three times with PBS, the medium was changed to serum-free media. The macrophages were cultured with serum-free medium for 24 h, and the conditional media were collected. Subsequently, the human trophoblast cell line, HTR-8 / SVneo (ATCC: CRL-3271), was used in the invasion assay with Matrigel (Corning). In brief, 1 x 105cells were placed in the transwell chamber (8 μM, Corning) containing serum-free conditioned medium derived from a 24 h culture of GSL-treated macrophages. The lower chamber contained RPMI 1640 complete medium with 10% FBS. After 24 h of incubation, the cells that had invaded the lower surface of the transwell chamber were fixed and stained with crystal violet. Three to five random views were photographed (100X) and quantified by counting the number of invading cells (total counts / field) with Image J software or colorimetric quantification.
[0112] Dot-blot assay for determination of GSL concentration
[0113] Supernatants from GSL-treated macrophages were collected, centrifuged at 1200×g for 10 min, and passed through 0.22 μm filter. The conditioned media was concentrated before loading into the membranes. The PVDF membranes were activated in MeOH, washed in PBS, and blocked for 30 min with 3% BSA in PBS. The membranes were incubated with anti-GHCer mAb or anti-SSEA3Cer mAb. After incubation with alkaline phosphatase-conjugated anti-bodied, immune-reactive GSL dots were detected by enhanced chemiluminescence reagents (Amersham Pharmacia Biotech, Amersham, UK) and analyzed by Typhoon (Cytiva). The optical density of dots detected by dot-blotting was calculated with ImageQuantTL (Cytiva).
[0114] Immunohistochemistry (IHC)
[0115] IHC analyses were performed on formalin-fixed, paraffin-embedded tissue. Sections (3 μm) on coated slides were deparaffinized and rehydrated, then subjected to antigen retrieval by autoclaving at 121°C for 5 min in antigen Retrieval AR-10 solution (BioGenex, USA). Sections were treated with H2O2and then incubated with anti-SSEA3Cer (MC-631, R&D Systems) at 4°C overnight, followed by staining with the Super SensitiveDocket no. 203-054PCT Polymer-HRP Detection System (BioGenex) and developed using DAB substrate (BioGenex). Slides were counter-stained with Harris’ hematoxylin and mounted. Sections were examined by pathologists and digital images were captured with an Aperio Scope AT Turbo Slide Scanner (Leica Biosystems, USA) at 20X magnification. The IHC results for all samples were judged by the same pathologist (Dr. Yenlin Huang, Chang Gung Memorial Hospital at Linko, Taoyuan, Taiwan).
[0116] Multiplex immunohistochemical analysis
[0117] Human decidual / placental specimens were assessed with multiplex immunohistochemical analysis, which provided simultaneous detection of SSEA3Cer and CD209 (Abclonal). Slides were heated at 60°C for 30 min and then Dewax (Leica Biosystems) was applied to remove any paraffin. Antigen retrieval was performed using ER2 buffer (Leica Biosystems) at 100°C for 30 min. Slides were washed and blocked with 3% H2O2blocking solution. Slides were incubated with the first primary antibody followed by the Opal polymer HRP secondary antibody (Akoya Biosystems, USA). After washing, tyramide signal amplification (TSA)-dye (Opal 7 color kit, Akoya Biosystems) for Position 1 was added. Slides were then heated to strip the primary and secondary antibodies, washed, and blocked again using blocking solution. The second primary antibody (Position 2) was added, and the process was repeated through Position 3, where DAPI was applied. After unbound DAPI was washed off, a coverslip was mounted using Vectashield (Vector Laboratories, USA). In addition to the multiplex assay described above, a single-color slide was generated for each antibody using archival TAA induced human decidua samples, as a control slide for comparison with standard IHC methods for CD209. Digital images of multiplex immunofluorescence staining were captured on a Leica DM6000 microscope (Germany) using the Leica Imaging Suite software. For initial image acquisition, exposure time was manually adjusted for each fluorochrome to minimize autofluorescence.
[0118] Example 1: Characterization of the isolated EVs derived from ESCs
[0119] EVs derived from ESCs were prepared via ultracentrifugation as described above and examined for morphological and molecular characteristics. In transmission electron microscopic image, EV displayed a round morphology with a lipidDocket no. 203-054PCT bilayer structure (Fig. 1A). The membranes of EVs are reported to be enriched with endosome-specific tetraspanins, such as CD9 and CD63. The isolated EVs derived from ESCs express CD9 and CD63 as shown in western blot analysis. (Fig. 1B). Nanoparticle tracking analysis revealed that the mean diameter of EVs was 134 ± 49 nm with a peak at ∼111 nm (Fig. 1C).
[0120] The GSL composition of the EVs was analyzed using a high-resolution protocol of MALDI-TOF MS. In the neutral fraction of EV extracts, the major components were GlcCer, LacCer, globotriaosylceramide (Gb3Cer), Gb4 / nLc4 ceramide (Gb4 / nLc4Cer), fucosyl Lc4 ceramide (Fuc-Lc4Cer), and two globo- series GSLs, such as SSEA3 ceramide (SSEA3Cer), and GHCer (Fig. 1D). In the acidic fraction of EV and ESC extracts, the major GSLs were GM3 ceramide (GM3Cer), GD3 ceramide (GD3Cer), GM1 ceramide (GM1Cer), and another globo-series GSLs, such as SSEA4 ceramide (SSEA4Cer) (Fig.1D). These globo-series GSLs detected in ESC-derived EVs were generally not found in the surface of mature cells of tissues but expressed abundantly in ESCs of early embryo before implantation. The sphingosine of the GSL ceramides in ESCs are d18:1 with N-acyl fatty chains of C16:0, C18:0, C20:0, C22:0, and C24:0. GSLs in both neutral and acidic extracts of EVs presented similar ceramide patterns, predominantly with C16 ceramide (Fig. 1D).
[0121] Example 2: Transfer of the globo-series GSLs from ESC-derived EVs to surface of CD14+and CD4+cells
[0122] PBMCs were cultured with ESC-derived EVs. As shown in Fig. 2A, the globo-series GSLs such as GHCer, SSEA3Cer, and SSEA4Cer were not detected by flow cytometric analysis on the cell surface of monocytes gated by CD14+. However, after 18 h incubation of PBMCs with EVs, these globo-series GSLs were observed to appear on the cell surface of monocytes gated by CD14+, compared with controls. Furthermore, with immunofluorescence staining (Fig. 2A), these globo-series GSLs, which were not detected originally in the isolated monocytes, were shown to appear in monocytes after 18 h incubation with EVs.
[0123] As shown in Fig. 2B, GHCer, SSEA3Cer, and SSEA4Cer could not be found in resting CD4+T cells with or without incubation with ESC-derived EVs. After activation of T cells with CD3 / CD28 conjugated beads, these globo-series GSLs were foundDocket no. 203-054PCT to accumulate on the T cell surface after similar incubation with ESC-derived EVs (Fig.2B). These findings thus suggest that incubation of PBMCs with EVs would transfer globo-series GSLs from ESC-derived EVs into the activated T cells, albeit not resting T cells.
[0124] Monocytes typically circulate through blood vessels and migrate into tissues, where they become macrophages. The monocytes from PBMCs could be induced ex vivo to become M0macrophages on day 7 and further polarized to M1and M2macrophages on day 9. To determine whether the globo-series GSLs in ESC-derived EVs could also be incorporated into macrophages, ESC-derived EVs were added after monocyte differentiated to become macrophage on day 7 (Top of Fig. 2C). Flow cytometric analysis of intact cells after 2 days indicated that macrophages, if incubated with ESC-derived EVs, had accumulated GHCer, SSEA3Cer, and SSEA4Cer on their surface (Bottom of Fig. 2C). β1,3-galactosyltransferase 5 (β3GALT5) is an enzyme essential for the biosynthesis of these three globo-series GSLs and β3GALT5-knockout (KO) clones were generated with CRISPR-Cas9 genomic editing. As shown in Fig. 2 Penel C, incubation of macrophages with EVs derived from these β3GALT5-KO-ESCs did not exhibit the transfer of GHCer, SSEA3Cer, and SSEA4Cer to macrophage based on flow cytometric analysis. These findings thus validate the transfer of globo-series GSLs from ESC-derived EVs to monocytes / macrophages.
[0125] Example 3: The globo-series GSLs in macrophage alter the expression of pro-inflammatory factors and decidual macrophage-related genes
[0126] To determine the effects of various EV-associated globo-series GSLs on macrophages, the globo-series GSLs in pure forms were used. As shown in Fig. 2D, the synthetic globo-series GSLs, such as GHCer or SSEA3Cer, were added on day 7 of monocyte culture. The flow cytometric analysis performed on day 9 indicated that GHCer and SSEA3Cer were incorporated into the surface of GSL-treated macrophages (Fig. 2D), similar to those transferred to macrophage surface via ESC-derived EVs (Fig. 2C).
[0127] To determine the effects of the globo-series GSLs on macrophage polarization, we followed the treatment protocol for monocyte / macrophage with EVs or synthetic globo-series GSLs added on day 7. The EV or GSL-treated macrophages were analyzed for the expression of various CD markers on day 9. In ESC-derived EV-treated macrophages, mRNA for the inducible nitric oxide synthase (iNOS, M1 marker) wasDocket no. 203-054PCT downregulated, and the expression of CD209 (decidual macrophage marker) was upregulated, whereas the expression of CD206 (M2 marker) showed no change with EV treatment (Fig. 3A, p < 0.05, n = 3). Similarly, in synthetic GSL-treated macrophages, the expression of iNOS was also downregulated, and the expression of CD209 was upregulated after treatment of macrophages with GHCer on day 7, whereas there was no change in the mRNA expression for CD206 (Fig. 3B).
[0128] Because the expression of iNOS was downregulated after treatment of macrophages with GSLs, we further examined the mRNA expression of pro-inflammatory cytokines / chemokines. The expressions of tumor necrosis factor (TNF), macrophage inflammatory protein 1 alpha (MIP1α), interleukin 23 (IL23), and interleukin 6 (IL6) were downregulated by treatment with synthetic SSEA3Cer in macrophages (Fig.3B, p < 0.05 or 0.01, n = 3). In addition, the mRNA expressions of TNF and IL6 were downregulated by GHCer treatment (Fig. 3B, p < 0.05, n = 3). The mRNA expression of IL6 was also downregulated by GlcCer treatment (Fig. 3B, p < 0.05, n = 3).
[0129] The important decidual macrophage-related gene expression by GSL- treated macrophages was examined. The data showed that the expression of the decidual macrophage-related genes, such as TREM2, NRP1, and CXCL1, were upregulated by SSEA3Cer treatment (Fig. 3B, p < 0.05 or 0.01, n = 3). However, GHCer treatment upregulated the expressions of CXCL1 and MMP9 (Fig.3B, p < 0.05, n = 3). Therefore, the globo-series GSLs added to the culture medium decreased the mRNA expression of both iNOS and pro-inflammatory cytokines / chemokines but increased the expression of decidual macrophage-related genes during macrophage differentiation.
[0130] Example 4: Transfer of the globo-series GSLs from ESC-secreted EVs enhances the phagocytic activity of macrophages
[0131] Enhanced phagocytosis is an essential feature of the macrophages in decidua that promotes embryo implantation. The effect of the globo-series GSLs transfer from ESC-secreted Evs on phagocytic activity of macrophages was examined. 100 μg of the isolated Evs were added after monocyte differentiation to become macrophage at day 7 (top of Fig. 4A). On Day 9, the phagocytic activity for fluorescein isothiocyanate (FITC)- conjugated-dextran by macrophage was analyzed with flow cytometry by the uptake of FITC-labeled extra beads. Bottom portion of Fig. 4A shows the phagocytic activity ofDocket no. 203-054PCT macrophages after treatment with Evs was significantly enhanced by 242.4% ± 26.9% (p < 0.001, n = 3).
[0132] To validate that the effect on phagocytic activity of macrophages was attributed to GHCer and SSEA3Cer in Evs, the GSL transfer experiments using the Evs generated from β3GALT5-KO ESCs performed. As shown in Fig. 4A, the phagocytic activity of macrophages after treatment with KO Evs was significantly enhanced by 156.6% ± 23.3% (p < 0.05, n = 3). Importantly, the phagocytic activity in KO EV-treated macrophages was reduced significantly compared with ESC EV-treated macrophages (p < 0.01, n = 3) (Fig. 4A).
[0133] Synthetic GSLs in pure form was used to examine which globo-series GSLs associated with EVs affects the phagocytic activity of macrophages. It was found that treatment with SSEA3Cer and GHCer enhanced the phagocytic activity of macrophages (196% ± 55% and 179% ± 72%, respectively) (Fig. 4A).
[0134] Fig.3C shows mRNA expression of TREM2 was upregulated, particularly with SSEA3Cer treatment during macrophage differentiation. To examine whether enhanced phagocytic activity observed in GSL-treated macrophages was mediated through TREM2, the GHCer-treated or SSEA3Cer-treated macrophages were pre-treated with anti- TREM2 antibody to block the TREM2 signaling, and the phagocytosis assay was conducted. As shown in Fig. 4B, the phagocytosis of FITC-dextran by the SSEA3Cer-treated macrophages, if pre-treated with anti-TREM2 antibody, was significantly reduced, compared with the control and treatment with isotype immunoglobulin G (IgG) antibody (p < 0.05, n = 5). In addition, the phagocytic activity of GHCer-treated macrophages was significantly reduced compared with the control (p < 0.05, n = 5). These findings indicate that SSEA3Cer promotes the TREM2-mediated phagocytic activity of macrophages.
[0135] To determine whether GSLs in PSC-derived EVs could be transferred into macrophages, the PSC-derived EVs were added to macrophage on day 7 and flow cytometric analysis was performed on day 9. The result shows GHCer, SSEA3Cer, and SSEA4Cer were found in macrophages after incubation with either HUES6- or iPS71-derived EVs. In contrast, these globo-series GSLs were not found to transfer onto macrophages after similar incubation with HUES6 KO (Fig. 9A).
[0136] To examine whether the transfer of the globo-series GSLs from PSC-Docket no. 203-054PCT derived Evs would affect the phagocytic activity of macrophages, 70 μg of the isolated EVs were co-cultured with macrophage at day 7 and the phagocytic activity for FITC- conjugated dextran by macrophage was analyzed with flow cytometry on day 9 (Fig.9B). It was shown that phagocytic activity of macrophages after treatment with these HUES6- derived and iPS71-derived EVs were enhanced by 142.4% ± 8.8% and 158.8% ± 27.9%, respectively (p < 0.05 and p < 0.01, respectively; n = 3, Fig. 9B). By comparison, the phagocytic activity of macrophages after treatment with HUES6 KO EVs was not enhanced (99.8% ± 5.9%, n = 3, Fig. 9B). Taken together, these findings support the idea that globo- series GSLs in PSC-derived EVs could translocate GSLs into macrophages to modulate the immune functions.
[0137] Example 5: The globo-series GSLs in macrophage affect T cell proliferation
[0138] To examine whether the GSLs transferred to macrophages suppress the proliferation of CD4+T cells, macrophages at day 7 of monocyte differentiation were treated with 30 μM synthetic GSLs for 2 days (Fig.5, top of Pane A). The GSL-treated macrophages were washed three times with PBS and co-cultured with autologous activated T cells, stimulated with anti-CD3 and anti-CD28. After incubation for 3 more days, GHCer present in macrophages was detected on the surface of T cells on day 12 using flow cytometric analysis (bottom of Fig. 5A). Similarly, SSEA3Cer in SSEA3Cer-treated macrophages was found to be transferred to T cells after co-culture (bottom of Fig. 5A).
[0139] The effect of the synthetic GSLs was investigated by determining the effects of macrophages on T cell proliferation using the cell permeant dye, carboxyfluorescein diacetate succinimidyl ester (CFSE). As shown in Fig. 5B, dye- dilution patterns of CFSE indicated that the proliferation of CD4+T cells after co-culture with GHCer-treated macrophages was significantly decreased compared with the sample with stimulated T cell control (blue), implying the transfer of GHCer and inhibition of proliferation of the stimulated T cells. Quantitatively, GHCer caused the T cell to decrease proliferation by as much as 74% ± 21% (p < 0.05, n = 5). Similarly, the decrease of T cell proliferation by GHCer was noteworthy when compared with those treated with GlcCer or SSEA3Cer, suggesting the specific selection of GHCer as the cause of proliferation inhibition. Interestingly, after co-culture with GHCer-treated macrophages, T cellDocket no. 203-054PCT proliferation was at the same level as that for the resting CD4+T cells (Fig.5B).
[0140] Therefore, the transfer of GHCer from macrophages to T cells suppressed T cell proliferation. Additional data also shows GHCer-treated macrophages had upregulated expressions of IDO-1 and CXCL2 compared with the controls (p < 0.05, n = 3), consistent with previous reports (Curti et al., 2009; Lee et al., 2012; Munn et al., 1999; Munn et al., 1998; Stadtmann and Zarbock, 2012) that this enzyme and chemokine inhibit T cell proliferation.
[0141] Example 6: The globo-series GSLs promote trophoblast invasion
[0142] During normal pregnancy, decidual macrophages play essential roles in trophoblast invasion, a key process during human placentation. To investigate whether the EV-associated globo-series GSLs in macrophages would enhance the ability of macrophages for trophoblast invasion, various synthetic GSLs were added to M0 macrophages on day 7 of monocyte differentiation (Fig. 6). On day 9, the samples were washed three times with PBS, the medium was replaced with serum-free medium, and the cells were incubated for another day to generate conditioned medium. Subsequently, the trophoblast invasion assay was conducted. Human trophoblast cells, HTR-8 / Svneo, were seeded in a pre-coated transwell chamber containing the conditioned media collected from various GSL-treated macrophages. After incubation for 24 h, the cells that had invaded to the lower surface of the transwell chamber, were stained and analyzed as described in Materials and Methods. Trophoblast invasion increased after incubation with the conditioned medium obtained from macrophages co-cultured with GHCer- or SSEA3Cer (200% ± 51%, p < 0.001 or 186% ± 33%, p < 0.01, respectively; n = 5) (Fig. 6). In contrast, there was no change in trophoblast invasion with the conditioned medium after GlcCer treatment. These results suggest that the globo-series GSLs such as GHCer or SSEA3Cer specifically enhanced the ability of macrophages for trophoblast invasion. In addition, dot blot analysis was performed to detect the content of GSL in the conditioned medium. The data showed that the conditioned medium of GHCer-treated macrophages contained 20 ± 8.1uM GHCer (Fig. 10A-C), while the conditioned medium of SSEA3Cer-treated macrophage contained 7.8 ± 2uM SSEA3Cer (Fig. 10D-F).
[0143] Moreover, the HTR-8 / SVneo trophoblast cell line was treated with synthetic globo-series GSLs. As shown in Fig. 11, the synthetic globo-series GSLs such asDocket no. 203-054PCT GHCer or SSEA3Cer were added in HTR-8 / SVneo. Then 18 hours later, the flow cytometric analysis of intact cells indicated that GHCer and SSEA3Cer were incorporated into the surface of GSL-treated HTR-8 / SVneo. Transwell assays were then performed to determine whether the specific synthetic GSLs stimulates trophoblast invasion. In Fig. 11, GHCer or SSEA3Cer led to improving trophoblast invasion (N=3, P<0.05).
[0144] Example 7: The expression of globo-series GSLs in decidual / placental tissues
[0145] Paraffin-embedded human placental tissue sections from elective first- trimester abortions, were obtained and stained using IHC staining with specific monoclonal antibodies against SSEA3Cer. Review of the IHC results in all cases was performed by the same pathologist. Positive IHC staining from representative human decidual specimens is shown in Fig. 7A, which illustrates heterogeneous IHC staining patterns of SSEA3Cer. In most cases, SSEA3Cer positive cells were dispersed throughout the placental tissues with granular staining of nuclei.
[0146] Multiplex immunohistochemical analysis was performed to provide the intuitive visualization and characterization of decidual tissue sections. Analyses of SSEA3Cer and the CD marker of decidual macrophages (CD209) were performed on the same FFPE slide (Fig. 7B). After alignment and merging of images, pseudocolors representing each combination were applied. The results showed the presence of CD209+cells with variable expression of SSEA3Cer in the decidual microenvironment from elective first-trimester abortions (arrows in Fig. 7B).
[0147] Example 8: The transfer of GSLs from trophoblast-derived EVs enhance the phagocytic activity of macrophages
[0148] To address the question whether EVs could be derived from first-trimester placental tissues to be used in the in vitro assays, we had EVs collected from first-trimester primary trophoblasts from a total of five different individuals. Then, these EVs were characterized first with EV marker, CD63, in electron microscopy with immunogold (Figure 12A). These EVs were also analyzed by nanoparticle tracking analysis and shown to have diameter of 156 nm (Figure 12A). Afterward, to determine whether GSLs in these trophoblast-derived EVs collected from first-trimester placental tissues could be incorporated into macrophages, EVs were added after monocyte differentiated to becomeDocket no. 203-054PCT macrophages on day 7. 2 days later, flow cytometric analysis showed that macrophages, if incubated with trophoblast-derived EVs (4 out of 5 samples, EV1–EV4) had accumulated GHCer, SSEA3Cer, and SSEA4Cer on their surface (Figure 12A).
[0149] Furthermore, to examine whether transfer of globo-series GSLs from the trophoblast-derived EVs would affect the phagocytic activity of macrophages, 100 mg of the isolated EVs were added to macrophages at day 7 (Figure 12B). Then, the phagocytic activity for FITC-conjugated-dextran by macrophages analyzed with flow cytometry by the uptake of fluorescence 2 days later. It was shown that phagocytic activity of macrophages after incubation with EVs was enhanced by 173.9% ± 14.9% (Figure 12B) (p < 0.05, n = 5).
[0150] Fig. 8 schematically illustrate that the globo-series GSLs, including but not limited to, GHCer and SSEA3Cer, from PSC-secreted EVs or synthetic nature, can be incorporated into monocytes and primed the differentiation toward decidual macrophages displaying features in favor of embryo implantation. First, co-culture of M0macrophages with EVs or specific synthetic globo-series GSLs lead to polarization and downregulation of the M1 marker, iNOS, whereas the decidual macrophage marker, CD209, was upregulated. Second, EVs or specific GSLs enhanced the phagocytic activity, the expression of the protease (MMP9), and the pro-angiogenesis factor (NRP1), and GSLs also promoted the trophoblast invasion, which may lead to tissue remodeling and facilitate embryo implantation and placentation. Third, the suppression of T cell proliferation and the lower expression of inflammatory substances (TNF, MIP1α, IL23, and IL6) enhance immune suppression in the decidual milieu. In addition, co-culture of M0 macrophages with GSLs increased the capacity for trophoblast invasion. In addition, the expression of CXCL1 was upregulated by treatment with GHCer or SSEA3Cer during monocyte differentiation, accounting for the increase in trophoblast invasion caused by these GSLs. Noteworthily, it was shown that decidual macrophages in tissue from first-trimester abortions expressed SSEA3Cer. The globo-series GSLs from ESC-secreted EVs promote trophoblast invasion for successful implantation.
Claims
Docket no. 203-054PCT CLAIMS What is claimed is:
1. A method for increasing embryo implantation rate in a subject, comprises the step of administering a composition comprising an effective amount of a glycosphingolipid to the subject in need thereof.
2. The method of claim 1, wherein the glycosphingolipid is expressed on the surface of macrophages, T cells, or trophoblasts.
3. The method of claim 1, wherein the composition comprises a conditioned medium.
4. The method of claim 3, wherein the conditioned medium is obtained from the co-culture of one or more macrophages with a glycosphingolipid for at least 24 hours.5.The method of claim 1-4, wherein the glycosphingolipid is GHCer, SSEA3Cer, SSEA4Cer, a derivative thereof or any combination thereof.
6. The method of claims 1, wherein the glycosphingolipid is derived from an extracellular vesicle (EV) secreted from pluripotent stem cells (PSCs) or trophoblasts.
7. The method of claim 1, wherein the glycosphingolipid is synthetic glycosphingolipid.
8. The method of claim 1, wherein the composition is administered into the reproductive structure of the subject.
9. The method of claim 1, wherein the composition is simultaneously administered with, before or after the administration of semen, an oocyte, or an embryo into the reproductive structure of the subject.10.The method of claim 1, further comprising the administration of one or more therapeutic agent that enhance embryo implantation.
11. A method for increasing embryo implantation rate in a subject, comprises the step of administering at least one embryo into the reproductive structure of the subject, said embryo expresses a glycosphingolipid.
12. The method of claim 11, further comprising the administration of a composition comprising an effective amount of a glycosphingolipid.
13. The method of claim 12, wherein the glycosphingolipid is expressed on the surface of macrophages, T cells, or trophoblasts.
14. The method of claim 12, wherein the composition comprises a conditioned medium.Docket no. 203-054PCT 15. The method of claim 14, wherein the conditioned medium is obtained from co-culture of one or more macrophages with a glycosphingolipid for at least 24 hours.
16. The method of claim 11-14, wherein the glycosphingolipid is GHCer, SSEA3Cer, SSEA4Cer, a derivative thereof or any combination thereof.17.The method of claims 12, wherein the glycosphingolipid is derived from an extracellular vesicle (EV) secreted from pluripotent stem cells (PSCs) or trophoblasts.
18. The method of claim 12, wherein the glycosphingolipid is synthetic glycosphingolipid.19.The method of claim 11, further comprising the administration of one or more therapeutic agents that enhance embryo implantation.
Citation Information
Patent Citations
Method for enhancing embryo implantation
US20210213053A1
